Combination treatment of the oral CHK1 inhibitor, SRA737 and low dose gemcitabine, enhances the effect of PD-L1 blockade by modulating the immune microenvironment in small cell lung cancer Meeting Abstract


Author: Sen, T.
Abstract Title: Combination treatment of the oral CHK1 inhibitor, SRA737 and low dose gemcitabine, enhances the effect of PD-L1 blockade by modulating the immune microenvironment in small cell lung cancer
Meeting Title: 34th Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2019)
Journal Title: Journal for ImmunoTherapy of Cancer
Volume: 7
Issue: Suppl. 1
Meeting Dates: 2019 Nov 6-10
Meeting Location: National Harbor, MD
ISSN: 2051-1426
Publisher: Biomed Central Ltd  
Date Published: 2019-11-01
Start Page: 282
Language: English
ACCESSION: WOS:000496473200672
PROVIDER: wos
PMCID: PMC6833189
PUBMED: 31694725
DOI: 10.1186/s40425-019-0763-1
Notes: Meeting Abstract: P250 -- Source: Wos
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Triparna Sen
    56 Sen